Table 1.
Selected clinical trials with therapy related to HR+/HER2− breast cancer based on palbociclib and letrozole according to the Clinicaltrials.gov database.
| NCT Number | Phase | Status | Conditions | Sponsor/Study Start | Intervention | Literature |
|---|---|---|---|---|---|---|
| NCT00721409 (PALOMA-1/TRIO-18) | I/II | completed | ER+/HER2− ABC | Pfizer/2008 | letrozole, palbociclib |
[33] |
| NCT01684215 | I/II | completed | Japanese postmenopausal women with ER+/HER2− ABC | Pfizer/2012 | letrozole, palbociclib |
[36,37] |
| NCT01740427 (PALOMA-2) | III | completed | postmenopausal women with ER+/HER2− ABC | Pfizer/2013 | letrozole, palbociclib, placebo |
[34] |
| NCT02297438 (PALOMA-4) | III | active, not recruiting | Asian postmenopausal women with ER+/HER2− ABC | Pfizer/2015 | letrozole, palbociclib, placebo |
[35] |
|
NCT02296801 (PALLET) |
II | completed | ER+ EBC | NSABP Foundation Inc./2015 | letrozole, palbociclib |
[38] |
| NCT02600923 | III | completed | postmenopausal women with HR+/HER2− BC | Pfizer/2015 | letrozole, palbociclib |
[39] |
| NCT02679755 | IV | completed | postmenopausal women with HR+/HER2− BC | Pfizer/2016 | letrozole, palbociclib |
[40] |
| NCT02764541 (PELOPS) | II | active, not recruiting | HR+ early-stage BC | Dana-Farber Cancer Institute/2016 | letrozole, tamoxifen, palbociclib |
|
| NCT02907918 (PALTAN) | II | terminated | HR+/HER2+ early-stage BC | Washington University School of Medicine/2017 | letrozole, trastuzumab, gorselin, palbociclib |
[41] |
| NCT03633331 | II | active, not recruiting | HR+/HER2− MBC | Alliance for Clinical Trials in Oncology/2018 | letrozole, fulvestrant, palbociclib |
[42] |
BC, breast cancer; ABC, advanced breast cancer; EBC, early breast cancer; MBC, metastatic breast cancer.